From the publishers of JADPRO

Myeloproliferative Neoplasms Resource Center

Advertisement

Characteristics of ruxolitinib discontinuation syndrome in myelofibrosis

Among patients with myelofibrosis treated with ruxolitinib, ruxolitinib discontinuation syndrome (RDS) occurred in 13.5% of patients, and was severe in only 1.2% of patients. Of the patients who developed RDS, 61.8% experienced mild symptoms, including discomfort related to splenomegaly, fatigue, pruritis, bone pain, and B-symptoms, according to abstract data presented at the 2020 European Hematology Association Annual Congress.

Cancer Therapy Advisor
Advertisement
News & Literature Highlights
Advertisement
Advertisement